MaxCyte vs OmniAb
MXCT and OABI side by side, both in engineering, accounting, research, management, and related services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MXCT and OABI compare
OmniAb is the larger company, worth 6.6 times as much as MaxCyte ($744M against $114M).
OmniAb grew revenue faster over the last twelve months (90.6% versus −0.13% for MaxCyte).
MaxCyte keeps more of each dollar of sales as profit, with a net margin of −81.4% compared with −108% at OmniAb.
MaxCyte scores higher on the StockData Score (11 against 9 for OmniAb), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MXCT | OABI |
|---|---|---|
| Size and price | ||
| Market cap | $114M | $744M |
| Share price | $1.10 | $5.10 |
| Change, 1 year | −25.2% | 242% |
| Change, 5 years | −91.4% | −48.8% |
| Beta (5Y) | 1.53 | 1.11 |
| Employees | 91 | 107 |
| StockData Score | ||
| Total score | 11 (better) | 9 |
| Valuation score | 3 (better) | 1 |
| Growth score | 2 (better) | 1 |
| Performance score | 1 | 1 |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 3.3× (better) | 18.5× |
| P/B | 0.8× (better) | 3.0× |
| P/FCF | – | 313× |
| FCF yield | −18.9% | 0.32% (better) |
| Fair value | $3.17 | $3.39 |
| Margin of safety | 65.3% (better) | −50.3% |
| Growth | ||
| Revenue growth (TTM) | −0.13% | 90.6% (better) |
| Revenue growth, 5Y average | 4.8% | – |
| Profitability | ||
| Gross margin | 81.0% | – |
| Operating margin | −98.0% (better) | −116% |
| Net margin | −81.4% (better) | −108% |
| FCF margin | −62.4% | 5.9% (better) |
| Return on equity | −16.9% | −16.5% (better) |
| Return on invested capital | −42.9% | −18.3% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 7.83 (better) | 4.21 |
| Altman Z-score | 0.31 | 9.58 (better) |
| Piotroski F-score | 2 | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 61.3% | 42.4% |
| Held by insiders | 8.0% | 5.9% |
| Insider net buying, 12 months | −$8.3K (better) | −$283K |
| Short interest, % of float | 1.7% | – |
Go deeper
- MXCT stock overview
- MXCT income statement
- MXCT valuation and score
- OABI stock overview
- OABI income statement
- OABI valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.